Your Health, We Care
On February 11, 2025, the U.S. Food and Drug Administration (FDA) approved mirdametinib for the treatment of adult and pediatric patients with plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN).
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
